Eve & Co Commences Canadian Medical Sales through Cannalogue
02 April 2020 - 11:00PM
Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V:
EVE; QTCQX: EEVVF) is pleased to announce that it has, through its
wholly-owned subsidiary Natural MedCo Ltd., entered the Canadian
medical cannabis market through its product listing agreement with
Cannalogue (1961628 Ontario Corp., doing business as Cannalogue)
entered into on March 9, 2020 (the “Product Listing Agreement”).
Cannalogue operates an e-commerce platform for the sale of products
to medical patients in Canada and holds a direct-to-sales licence
issued by Health Canada.
The Product Listing Agreement allows Eve &
Co to list its products for sale to medical patients on the
Cannalogue platform. The Company has listed an assortment of
pre-roll and dried flower products on the platform and has
commenced sales as of April 1, 2020.
“Listing our products on Cannalogue is a
tremendous opportunity for Eve & Co to continue building its
national distribution network and provide medical patients with
access to our products,” said Melinda Rombouts, President and CEO
of Eve & Co.
About Eve & Co
Incorporated
Eve & Co, through its wholly-owned
subsidiary Natural MedCo Ltd., holds cultivation and processing
licences under the Cannabis Act (Canada) for the production and
sale of various cannabis products, including dried cannabis,
cannabis plants and extraction of cannabis oil and has received EU
GMP certification. Natural MedCo Ltd. was Canada’s first
female-founded licensed producer of medicinal marijuana and
received its cultivation licence from Health Canada in 2016. Eve
& Co is led by a team of agricultural experts and has a
licensed 1,000,000 square foot greenhouse located in Strathroy,
Ontario.
The Company’s website can be visited at
www.evecannabis.ca.
About Cannalogue
Based in Toronto, Cannalogue is a rapidly
emerging healthcare technology company that received Health
Canada's first direct-to-sales licence for medical cannabis.
Cannalogue's innovative technology provides a safe, controlled, and
cost-effective online marketplace that is globally scalable into
all medical cannabis markets. Engineered by physicians
Dr. Mohan Cooray and Dr. Andrew Lu, Cannalogue
challenges the status quo and advocates on behalf of patients to
educate medical professionals and government officials on the
safety and benefits of medical cannabis as a viable treatment
option to traditional therapies. The Company’s website can be
visited at www.cannalogue.ca.
Neither the TSX Venture Exchange nor its
regulation services provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Notice regarding forward looking
statements:
Certain statements in this press release
constitute forward-looking information. All statements other than
statements of historical fact contained in this press release,
including, without limitation, those regarding the Company’s
expected sales to the Canadian medical cannabis markets,
opportunities for growth, future, strategy, plans, objectives,
goals and targets, and any statements preceded by, followed by or
that include the words “believe”, “expect”, “aim”, “intend”,
“plan”, “continue”, “will”, “may”, “would”, “anticipate”,
“estimate”, “forecast”, “predict”, “project”, “seek”, “should” or
similar expressions or the negative thereof, are forward-looking
statements. These statements are not historical facts but instead
represent only the Company’s expectations, estimates and
projections regarding future events. These statements are not
guarantees of future performance and involve assumptions, risks and
uncertainties that are difficult to predict, including those
described in the Company’s management’s discussion and analysis for
the three and nine month periods ended September 30, 2019 which is
available on the Company’s SEDAR profile. Therefore, actual results
may differ materially from what is expressed, implied or forecasted
in such forward-looking statements. The forward-looking information
and forward-looking statements included in this news release are
made as of the date of this news release. The Company does not
undertake an obligation to publicly update such forward-looking
information or forward-looking information to reflect new
information, subsequent events or otherwise unless required by
applicable securities law.
For further information, please contact:
Melinda Rombouts President and Chief Executive Officer Eve & Co
Incorporated Telephone: (855)
628-6337
Melanie Greco Public Relations Cannalogue Telephone: (647)
456-2653
Eve & (TSXV:EVE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eve & (TSXV:EVE)
Historical Stock Chart
From Jul 2023 to Jul 2024